IDEA - Gilde Healthcare



Munich, Germany

Pain Management
Since: 2005
Exit: 2010

IDEA focused on non-invasive topical delivery of approved pain relief drugs.

Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.

IDEA was located in Munich, Germany.

More IDEA news

IDEA AG – US Patent Office grants a new patent

IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®

IDEA AG gives an update on the development of Diractin®, the targeted analgesic

IDEA AG receives two milestone payments ($37 million) from partner Alpharma